Navigation Links
Cardiologists initiate STILETTO study to investigate treatment options for women with chest pain
Date:2/24/2009

CHICAGO Women who experience chest pain are sent to a cardiologist to go through a standard battery of tests, and often times test results show no evidence of coronary artery disease which is the most common cause of chest pain. This is a less common occurrence in men, and these women are sent home with little more than reassurance but often times return to their physicians complaining of similar symptoms and are more likely to develop future cardiac events.

To better determine the cause of difficult to diagnose chest pain among women, physicians at Northwestern Memorial's Bluhm Cardiovascular Institute are initiating a research study designed to identify the prevalence of a condition called Syndrome X. This disease process affects the endothelial function of blood vessels, a condition where the layers of the cells are not functioning properly and may be undetectable by standard testing such as exercise stress test and cardiac angiography. Researchers believe that endothelial dysfunction is the earliest stage of coronary artery disease. The goal of the study is to determine a more accurate diagnosis for women who present with chest pain symptoms and to determine if a more aggressive treatment regimen than the current standard of care may be adopted in the future.

In women there may be a different disease process which could be due to endothelial dysfunction, which is not something that can be detected by the current standard of care regimen. "Given that endothelial dysfunction may be an early stage of atherosclerosis, or fat deposits in the arteries, some have suggested medical treatment and lifestyle changes similar to those recommended to women with obstructive coronary artery disease," says Martha Gulati, MD, associate medical director of the Center for Women's Cardiovascular Health and assistant professor of medicine at Northwestern University's Feinberg School of Medicine.

"There are currently no other randomized trials comparing the effectiveness of such therapy in women with cardiac symptoms, normal coronary arteries but evidence of coronary endothelial dysfunction," commented Neil Stone, MD, medical director of the Center for Vascular Disease and professor of medicine at Northwestern University's Feinberg School of Medicine.

Study participants will undergo endothelial dysfunction testing, a procedure where medication is injected into the coronary arteries to directly assess endothelial response of the arteries, in order to identify women who may be likely to develop coronary artery disease and who would benefit from aggressive lifestyle and medical interventions. These interventions include dietary counseling, exercise, and medical treatment targeting improving the endothelial dysfunction.


'/>"/>

Contact: Amy Dobrozsi
adobrozs@nmh.org
312-926-5900
Northwestern Memorial Hospital
Source:Eurekalert

Related medicine news :

1. One-Third of U.S. Primary Care Physicians and Cardiologists Do Not Currently Prescribe Treatment to Meet HDL Cholesterol Targets as Recommended By National Guidelines
2. Cardiologists Warn Proposed Changes Would Close Outpatient Cardiac Cath Labs
3. Cardiologists Spot Best Treatment for a Deadly Duo
4. Distinguished Cardiologists and Scientists Honored With 2008 International Academy of Cardiology Award
5. Dallas Cardiologists Explore Next Frontier in Vascular-Disease Treatments
6. Cardiogenesis Announces Successful Educational Symposium Targeted at Cardiologists at the TCT Meeting in Washington, D.C.
7. SCAIs Annual Fall Fellows Course Prepares New Interventional Cardiologists to Work in the Field
8. Res-Q Gains Rights To Market Orosine - a Breakthrough, Patented, Natural Heart Supplement That Cardiologists Are Calling the Ultimate Cardio Protection Against Heart Attacks, Strokes and Heart Failure.
9. Among Cardiologists, Women Cite Discrimination
10. Video: Cardiologists Recommend Lifestyle Habits for Healthy Hearts
11. Tyco International Increases Quarterly Dividend 36 Percent to 15 Cents per Share; Initiates New $1 Billion Share Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... ... July 24, 2017 , ... The Topricin Companies, ... awareness for Topricin’s revolutionary, natural, after-burn skin care product, Topricin After Burn Cream. ... of long term skin conditions, including cancer. In the short term, overexposure ...
(Date:7/24/2017)... ... 24, 2017 , ... A CDC study shows that, although people are taking more steps to ... 29), had at least one case of sunburn within the past year. It’s common and ... ignore the issue. However, only recently have people become conscientious of the risks that accompany ...
(Date:7/24/2017)... ... 2017 , ... Anyone who uses scales know they have limits; a small ... that same scale to dispense medication. The first example is an issue of capacity, ... it is important to have the right balance for the process. METTLER TOLEDO’s new ...
(Date:7/24/2017)... OR (PRWEB) , ... July 24, 2017 , ... Sharon ... Climate Change and Your Health on VoiceAmerica sponsored by Nature’s Tears® EyeMist® recently talked ... the rise of myopia in China. , The article by Zidor Aldama described the ...
(Date:7/24/2017)... ... July 24, 2017 , ... Paul Vitenas, MD, FACS is excited to report ... invited to attend Allergan’s recent meeting with their Plastics Advisory Board. As one of ... Allergan is bringing a newly defined structure to the aesthetics market. Dr. Vitenas ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... , July 11, 2017  Sysmex America, ... urinalysis diagnostic testing equipment as well as middleware ... a way to make quality assurance easier and ... "Sysmex is well known for the innovation that ... Quality Monitor elevates quality assurance processes to a ...
(Date:7/10/2017)... , July 10, 2017  BDI Group subsidiary ... patient support services organization serving specialty pharmacies, home ... launch of four significant, value-added member programs designed ... better manage reimbursement and improve access and affordability ... therapies. ...
(Date:7/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ... company focused on the development of oral drug delivery systems, ... Securities Authority to dual-list its common stock on the Tel ... on the TASE on July 12, 2017 under the ticker ... it is expected that Oramed will be included in the ...
Breaking Medicine Technology: